TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination
Two distinct federal initiatives are driving these changes: the Inflation Reduction Acts drug price negotiation program (effective January 2027) and a voluntary manufacturer pilot program (starting mid-2026)
You'll hear a lot about it in discussions about healing, tissue repair, and inflammation
Nausea, diarrhea, constipation, and reduced appetite are the most common
Common side effects are generally mild
Formally known as a class of medications called GLP-1 Receptor Agonists (GLP-1 RAs), GLP-1 agonists, or, more commonly, GLP-1s, these medications mimicking the bodys natural glucagon-like peptide (GLP-1) hormone